Spotlight on decitabine for myelodysplastic syndromes in Chinese patients

References

• TormoMMaruganICalabuigMMyelodysplastic syndromes: an update on molecular pathologyClin Transl Oncol2010121065266120947479
   PubMed Web of Science ®Google Scholar
• OrnsteinMCMukherjeeSSekeresMAMore is better: combination therapies for myelodysplastic syndromesBest Pract Res Clin Haematol2015281223125659727
   PubMed Web of Science ®Google Scholar
• LvLLinGGaoXCase-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese populationAm J Hematol201186216316921264898
   PubMed Web of Science ®Google Scholar
• KuangSLiangWClinical analysis of 43 cases of chronic benzene poisoningChem Biol Interact200515315412913516289500
   PubMed Web of Science ®Google Scholar
• KuendgenALubbertMCurrent status of epigenetic treatment in myelodysplastic syndromesAnn Hematol200887860161118392623
   PubMed Web of Science ®Google Scholar
• NavadaSCSteinmannJLubbertMSilvermanLRClinical development of demethylating agents in hematologyJ Clin Invest20141241404624382388
   PubMed Web of Science ®Google Scholar
• KellyTKDe CarvalhoDDJonesPAEpigenetic modifications as therapeutic targetsNat Biotechnol201028101069107820944599
   PubMed Web of Science ®Google Scholar
• CashenAFSchillerGJO’DonnellMRDiPersioJFMulticenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaJ Clin Oncol201028455656120026803
   PubMed Web of Science ®Google Scholar
• WeeSDhanakDLiHTargeting epigenetic regulators for cancer therapyAnn N Y Acad Sci20141309303624571255
   PubMed Web of Science ®Google Scholar
• HaladynaJNYamauchiTNeffTBerntKMEpigenetic modifiers in normal and malignant hematopoiesisEpigenomics20157230132025942537
   PubMed Web of Science ®Google Scholar
• JuoYYGongXJMishraAEpigenetic therapy for solid tumors: from bench science to clinical trialsEpigenomics20157221523525942532
   PubMed Web of Science ®Google Scholar
• AzadNZahnowCARudinCMBaylinSBThe future of epigenetic therapy in solid tumours – lessons from the pastNat Rev Clin Oncol201310525626623546521
   PubMed Web of Science ®Google Scholar
• HuangYWKuoCTStonerKHuangTHWangLSAn overview of epigenetics and chemopreventionFEBS Lett2011585132129213621056563
   PubMed Web of Science ®Google Scholar
• BejarRSteensmaDPRecent developments in myelodysplastic syndromesBlood2014124182793280325237199
   PubMed Web of Science ®Google Scholar
• EstephanFTiuRVCurrent and novel therapeutic approaches in myelodysplastic syndromesJ Community Support Oncol201412723624925830232
   PubMedGoogle Scholar
• IshikawaTNovel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndromeInt J Clin Oncol2014191101524357411
   PubMed Web of Science ®Google Scholar
• GurionRVidalLGafter-GviliA5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome – a systematic review and meta-analysisHaematologica201095230331019773261
   PubMed Web of Science ®Google Scholar
• XieMJiangQXieYComparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participantsClin Lymphoma Myeloma Leuk2015151222825042977
   PubMed Web of Science ®Google Scholar
• XuJZhouYZhangJHigh incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutationClin Chim Acta201241315–161284128722546611
   PubMed Web of Science ®Google Scholar
• SugiyamaEKaniwaNKimSRPharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphismJ Clin Oncol2007251324217194903
   PubMed Web of Science ®Google Scholar
• IyerSNAnkalaASinghalRSHegdeMRDetermination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic populationGene20135241353923612254
   PubMed Web of Science ®Google Scholar
• EbrahemQMahfouzRZNgKPSaunthararajahYHigh cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effectsOncotarget20123101137114523087155
   PubMedGoogle Scholar
• MahfouzRZJankowskaAEbrahemQIncreased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapyClin Cancer Res201319493894823287564
   PubMed Web of Science ®Google Scholar
• LeeYGKimIYoonSSComparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromesBr J Haematol2013161333934723432512
   PubMed Web of Science ®Google Scholar
• OkiYKondoYYamamotoKPhase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in JapanCancer Sci2012103101839184722816487
   PubMed Web of Science ®Google Scholar
• UchidaTOgawaYKobayashiYPhase I and II study of azacitidine in Japanese patients with myelodysplastic syndromesCancer Sci201110291680168621624006
   PubMed Web of Science ®Google Scholar
• MusolinoCSant’antonioEPennaGEpigenetic therapy in myelodysplastic syndromesEur J Haematol201084646347320192987
   PubMed Web of Science ®Google Scholar
• SantosFPKantarjianHGarcia-ManeroGIssaJPRavandiFDecitabine in the treatment of myelodysplastic syndromesExpert Rev Anticancer Ther201010192220014881
   PubMed Web of Science ®Google Scholar
• BryanJKantarjianHGarcia-ManeroGJabbourEPharmacokinetic evaluation of decitabine for the treatment of leukemiaExpert Opin Drug Metab Toxicol20117566167221500965
   PubMed Web of Science ®Google Scholar
• SaunthararajahYSekeresMAdvaniAEvaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromesJ Clin Invest201512531043105525621498
   PubMed Web of Science ®Google Scholar
• MomparlerRLPharmacology of 5-aza-2′-deoxycytidine (decitabine)Semin Hematol2005423 Suppl 2S9S1616015507
   PubMed Web of Science ®Google Scholar
• SeymourJFFenauxPSilvermanLREffects of azacitidine compared with conventional care regimens in elderly (>/=75 years) patients with higher-risk myelodysplastic syndromesCrit Rev Oncol Hematol201076321822720451404
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
   PubMed Web of Science ®Google Scholar
• ChristiansenDHAndersenMKPedersen-BjergaardJMethylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemiaLeukemia20031791813181912970781
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer200610681794180316532500
   PubMed Web of Science ®Google Scholar
• LubbertMWijermansPKunzmannRCytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidineBr J Haematol2001114234935711529854
   PubMed Web of Science ®Google Scholar
• WijermansPLubbertMVerhoefGLow-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsJ Clin Oncol200018595696210694544
   PubMed Web of Science ®Google Scholar
• SabaHRosenfeldCIssaJPFirst report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS)Blood200410423a
   Web of Science ®Google Scholar
• YeeKWJabbourEKantarjianHMGilesFJClinical experience with decitabine in North American patients with myelodysplastic syndromeAnn Hematol200584Suppl 1182416273408
   PubMed Web of Science ®Google Scholar
• van den BoschJLubbertMVerhoefGWijermansPWThe effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromesLeuk Res200428878579015203276
   PubMed Web of Science ®Google Scholar
• SabaHLubbertMWijermansPWResponse rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS)Blood2005106706a15802527
   PubMed Web of Science ®Google Scholar
• HuQJChenBARecent advances in therapy of myelodysplastic syndromesZhongguo Shi Yan Xue Ye Xue Za Zhi20122061522152523257466
   PubMedGoogle Scholar
• VisconteVTiuRVRogersHJPathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the diseaseBlood res201449421622725548754
   PubMedGoogle Scholar
• LiJChenYZhuYEfficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaOncotarget2015686448645825749041
   PubMedGoogle Scholar
• GreenbergPLAttarEBennettJMNCCN clinical practice guidelines in oncology: myelodysplastic syndromesJ Natl Compr Canc Netw201191305621233243
   PubMed Web of Science ®Google Scholar
• XiaoZDecitabine in myelodysplastic syndromes: the current status and futureZhonghua Xue Ye Xue Za Zhi201435318518624666480
   PubMedGoogle Scholar
• LvZClinical efficacy of low-dose demethylation treatment of myelodysplastic syndromeMudanjiang Yi Xue Yuan Xue Bao20143534748
   Google Scholar
• YangHZhuHYJiangMMClinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemiaZhongguo Shi Yan Xue Ye Xue Za Zhi201321112112523484704
   PubMedGoogle Scholar
• WangHWuYGeSLiuXTherapeutic effect of decitabine in treating middle and high risk myelodysplastic syndromeZhi Ye Wei Sheng Yu Bing Shang2014292108110
   Google Scholar
• CaoHWangZLuXZSWuZClinical research of patients with myelodysplastic syndromes and acute myeloid leukemia treated by decitabine with half quantity of CAG/CAOZhongguo Yi Xue Chuang Xin20141131131133
   Google Scholar
• ZhangXDengYZhangLFour case reports of sequential regimen of decitabine followed by half standard dose CAG in myelodysplastic syndrome and leukemic transformationBai Xi Bao Lin Ba Liu2012217433435
   Google Scholar
• GuanJJiangYSunAEffect of decitabine in combination with HAG/IAG regimen on elderly patients with AML and higher-risk MDSZhong Hua Lin Chuang Yi Shi Za Zhi201482138973900 Chinese
   Google Scholar
• ChenQZhaoLLingCEfficacy and safety of demethylation agents for middle/high-risk patients with myelodysplastic syndrome: a systematic reviewZhongguo Xun Zheng Yi Xue Za Zhi201414910971103
   Google Scholar
• YangBCaiLWangHTreatment of an elderly patient with acute myelocytic leukemia transformed from myelodysplastic syndrome with decitabine in ultra-low dosage combining with transfusion of autologous cytokineinduced killer cells: a case report and review of literatureJie Fang Jun Yi Xue Za Zhi2014394315319
   Google Scholar
• XiaoYFengJResearch progress of traditional Chinese Medicine on myelodysplastic syndromeZhong Yi Yao Xin Xi20052241719
   Google Scholar
• WuHPractical Traditional Chinese Hematology2nd edShanghai, People’s Republic of ChinaShanghai University of Traditional Chinese Medicine Press1996
   Google Scholar
• HuangZQiuZChenPChinese medicine treatment of MDS staging clinical experienceZhong Yi Wen Xian Za Zhi20072533335
   Google Scholar
• SunWMengXAdvances in the combined treatment of myelodysplastic syndrome with traditional Chinese and western medicineZhong Yi Yao Xin Xi20072461214
   Google Scholar
• ZhangHMaJComparison of traditional Chinese and western medicine treatment of myelodysplastic syndromeZhongguo Xian Dai Yi Sheng200846217185
   Google Scholar
• ZhuXQiuZChenPZhaoLHuangZHuXClinical efficacy of chinese medicine combined with decitabine in treatment of high risk myelodysplastic syndromesZhong Hua Zhong Yi Yao Xue Kan201432512401243
   Google Scholar